Get started
Author

Norbert Schmees

Observed names: N. SCHMEES, N. Schmees, Schmees, N., Schmees, Norbert
Institution: Nuvisan (Germany)
ORCID: 0000-0002-3284-3921
Observed ORCID: 0000-0002-3284-3921
OpenAlex ID: A5038885061
Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
2003 · Heike Schäcke, Arndt Schottelius, et al. · Proceedings of the National Academy of Sciences · 463
Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
2014 · Marie Jung, Martin Philpott, et al. · Journal of Biological Chemistry · 166
PDF
Enantioselective Heck Reactions Catalyzed by Chiral Phosphinooxazoline-Palladium Complexes
1997 · Olivier Loiseleur, Masahiko Hayashi, et al. · Synthesis · 143
Enantioselective Heck reactions using chiral P,N-ligands
1999 · Olivier Loiseleur, Masahiko Hayashi, et al. · Journal of Organometallic Chemistry · 133
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy
2023 · Christina Kober, Julian Roewe, et al. · Journal for ImmunoTherapy of Cancer · 104
PDF
Palladium(II) complexes with P,N‐ and C,N‐ligands as catalysts for the Heck reaction
2004 · Thomas Schultz, Norbert Schmees, et al. · Applied Organometallic Chemistry · 43
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
2017 · Elena Bernasconi, Eugenio Gaudio, et al. · British Journal of Haematology · 41
PDF
SEGRAs: A Novel Class of Anti-inflammatory Compounds
2002 · H. Schäcke, H. Hennekes, et al. · Springer eBooks · 38
Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21
2023 · Fabian Göricke, Victoria Vu, et al. · Journal of Medicinal Chemistry · 32
PDF
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening
2021 · Stefan Gradl, Holger Steuber, et al. · SLAS DISCOVERY · 32
PDF
Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women
2020 · Olaf Panknin, Andrea Wagenfeld, et al. · Journal of Medicinal Chemistry · 26
Discovery of quinolines as selective glucocorticoid receptor agonists
2010 · Stefan Jaroch, Markus Berger, et al. · Bioorganic & Medicinal Chemistry Letters · 24
Discovery of new selective glucocorticoid receptor agonist leads
2016 · Markus Berger, Hartmut Rehwinkel, et al. · Bioorganic & Medicinal Chemistry Letters · 16
Abstract 4454: Identification of BAY-218, a potent and selective small-molecule AhR inhibitor, as a new modality to counteract tumor immunosuppression
2019 · Norbert Schmees, Ilona Gutcher, et al. · Cancer Research · 14
Abstract 1288: Blocking tumor-associated immune suppression with BAY-218, a novel, selective aryl hydrocarbon receptor (AhR) inhibitor
2019 · Ilona Gutcher, Christina Kober, et al. · Cancer Research · 13
Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty
2005 · Uwe Pleyer, Jun Yang, et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 10
Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models
2015 · Pascale Lejeune, Tatsuo Sugawara, et al. · Cancer Research · 8
Abstract ND04: BAY 2965501: A highly selective DGK- ζ inhibitor for cancer immuno-therapy with first-in-class potential
2023 · Rienk Offringa, Catherine Olesch, et al. · Cancer Research · 7
737 Optimal enhancement of anti-tumor T-cell immunity through the combined use of selective DGK zeta and DGK alpha inhibitors
2024 · Rienk Offringa, Catherine Olesch, et al. · Journal for ImmunoTherapy of Cancer · 4
926 BAY 2965501: a highly selective DGK zeta inhibitor for cancer immunotherapy
2023 · Rienk Offringa, Catherine Olesch, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
Abstract 1646: Discovery and characterization of BAY-6035, a novel benzodiazepine-based SMYD3 inhibitor
2018 · Stefan Gradl, Holger Steuber, et al. · Cancer Research · 3
Progesterone Receptor: Overview of Modern Steroidal Progestins and Developments in the Field of Nonsteroidal Selective Progesterone Receptor Modulators
2008 · Klaus Schöllkopf, Norbert Schmees · Methods and principles in medicinal chemistry · 3
Recent patent trends in the field of progesterone receptor agonists and modulators
2009 · Norbert Schmees, Hilmar Weinmann · Expert Opinion on Therapeutic Patents · 2
Abstract 4749: New benzazepine BET-inhibitors with improved oral bioavailability
2014 · Norbert Schmees, Bernard Haendler, et al. · Cancer Research · 1
Abstract 6978: Discovery and characterization of BAY-805, a potent and selective DUB inhibitor of ubiquitin specific peptidase USP21
2025 · Norbert Schmees, Fabian Göricke, et al. · Cancer Research
Works count: 38
Citation count: 1,330
H-index: 14
I10-index: 16
Year
Topic
Type